Medical review by — Dr. Imran Khan, MD, IFMCP
Last medically reviewed: November 19, 2026
Understanding Approval and Access
Headlines about peptides and the FDA can leave patients with a practical question: does a change in compounding policy mean a treatment is now proven safe and effective? FDA approval, pharmacy compounding, and permission to conduct research are separate matters. An advisory committee recommendation does not turn an experimental peptide into an FDA-approved medication.
For patients considering care at Internal Healing and Wellness MD, understanding those differences can make a consultation more useful. The questions go beyond whether a peptide is available: what is the exact product, what human clinical trials support its proposed use, and what risks remain uncertain? As of November 13, 2026, the regulatory picture includes an October 30 draft federal enforcement policy published for public comment. This makes precise, dated information especially important.
Disclaimer: This information is for educational purposes only and does not replace medical advice. This article discusses United States federal regulation and medical evidence checked November 13, 2026. It is not legal advice. Regulatory policies and evidence can change, and state requirements may also apply. Discuss treatment decisions with a qualified clinician and specific dispensing questions with a licensed pharmacist.
What FDA Approval Actually Establishes
Peptides are chains of amino acids, the building blocks also found in proteins. Some act as signals in the body. However, belonging to this broad family says little about whether a particular medication works for a particular condition.
FDA-approved drugs undergo review of evidence supporting their safety and effectiveness, along with manufacturing and labeling information. Approval applies to a specific product and its approved uses. Certain semaglutide and tirzepatide products, for example, have approved uses in diabetes or weight management; a vial sold under the same ingredient name does not automatically share that approval.
An approved drug may also be prescribed off-label for an unapproved use when a clinician judges that appropriate. This differs from prescribing a substance that has no FDA-approved drug product. Neither situation should be described as FDA approval for the proposed treatment.
Compounding Has Its Own Rules
Compounding involves combining, mixing, or altering ingredients to meet a medical need. It can be valuable when an available approved medicine is unsuitable for a patient. Compounded drugs themselves are not FDA-approved, and the FDA does not review each preparation for safety, effectiveness, and quality before marketing. That does not mean compounding is free from oversight.
Two federal compounding pathways matter:
- Section 503A generally covers patient-specific compounding by licensed pharmacists or physicians.
- Section 503B covers registered outsourcing facilities, which operate under different requirements.
Under 503A, bulk ingredients must satisfy applicable statutory criteria involving a USP or NF monograph, use as a component of an approved drug, or inclusion on the 503A bulks list. FDA also maintains an interim enforcement policy for certain nominated ingredients. Meeting one requirement does not establish compliance with all the others.
This makes blanket statements about peptide compounding unreliable. FDA’s May 2026 nomination list places GHK-Cu for non-injectable routes in Category 1, where conditional enforcement discretion may apply. That entry excludes injections and does not confer FDA approval on a GHK-Cu preparation.
Peptides and the FDA in 2026
At its July 23–24, 2026 meeting, the Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax, and epitalon for potential inclusion on the 503A bulks list. HHS’s October 2026 policy document records favorable committee votes for BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500. The committee provides nonbinding advice to FDA. Its recommendations do not constitute drug approval or themselves change the codified compounding list.
On October 30, 2026, HHS published a draft enforcement discretion policy for 503A compounding of six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500, each limited to specified routes of administration.
It applies to state-licensed pharmacies and licensed physicians compounding under section 503A, not to 503B outsourcing facilities, and it sets conditions such as an FDA-registered manufacturer, a certificate of analysis, adverse-event reporting, and a patient-specific prescription. The policy is a draft, is not binding, does not approve any peptide, and is intended to apply only until FDA completes rulemaking on the bulks list.
The seven peptides reviewed at the July meeting do not appear on the current codified 503A bulks list checked for this article. Permanent list changes and interim enforcement policies are different regulatory actions. Patients should ask a prescriber and pharmacist to identify the current basis for supplying the exact preparation, rather than relying on a headline about a committee vote.
What Human Research Can Tell Us
The evidence varies by substance, condition, formulation, and route of administration. Laboratory findings about cellular activity cannot establish that peptide injections improve recovery or long-term health in people.
BPC-157 and Tissue Repair
BPC-157 is promoted for soft-tissue recovery and tissue repair, but it has no FDA-approved drug product. Human research exists, but it is limited. An October 2026 systematic review included three studies with 30 participants and rated the certainty of evidence very low because of methodological weaknesses and other limitations.
These findings do not establish reliable benefits, appropriate dosing, or long-term safety. FDA’s own review also identified insufficient clinical safety information and potential immunogenicity concerns, meaning the possibility of an unwanted immune response.
TB-500 and GHK-Cu
FDA describes TB-500 as a synthetic fragment of thymosin beta-4. Research on the full thymosin beta-4 molecule cannot automatically be applied to that fragment. FDA’s assessment found insufficient evidence to evaluate TB-500’s effectiveness for the nominated wound-healing use and a lack of human safety information.
GHK-Cu has a different evidence base, including topical research. A 2026 review of GHK-Cu research described small or incompletely characterized human studies. Results from a skin formulation cannot establish the safety or effectiveness of injectable GHK-Cu.
Other peptides, including thymosin alpha-1, CJC-1295, and ipamorelin, likewise require their own evidence review. A claim about one peptide cannot establish benefits for another.
Risks Include the Substance and Its Source
With unapproved peptides, uncertainty includes the substance’s biological effects as well as the product’s quality. A 2026 medical review of unregulated injectable products discussed contamination, manufacturing impurities, dosing problems, and potential biological harms. Its discussion of possible cancer-related mechanisms should not be read as proof that BPC-157 or TB-500 causes cancer in humans.
Research-only labeling does not make an online product suitable for treatment. In an August 2026 warning letter, FDA found that a seller’s marketing demonstrated intended human drug use despite research-only disclaimers. FDA also emphasized that injections bypass important defenses against microorganisms and toxins.
A certificate of analysis can provide useful information about a tested sample. Patients should not treat it as FDA approval or as a substitute for checking the dispensing source, finished preparation, and applicable quality requirements.
Compounded GLP-1 Medications Need Separate Review
Compounded semaglutide and tirzepatide are not interchangeable with FDA-approved products. Following resolution of their injection shortages and the applicable transition periods, shortage-related enforcement discretion no longer provides a general basis for making copies.
Under 503A, regular or inordinate compounding of essentially copies of commercially available drugs is restricted. A prescriber may determine that a change produces a significant difference for an identified patient, but the determination must reflect that patient’s circumstances. FDA’s September 2026 Empower Pharmacy warning letter questioned repeated, apparently pre-generated justifications.
Separately, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. The May 2026 Federal Register notice is a proposal, not itself a final determination.
Questions to Bring to a Consultation
Before considering a peptide treatment, ask:
- What exact product and formulation are being proposed, and what is their FDA status?
- What human evidence supports this use and route of administration?
- If it is compounded, which pharmacy or facility will prepare it, and what rules apply?
- What benefits are realistic, what risks remain unknown, and what alternatives are available?
- What follow-up is appropriate, and what symptoms should prompt medical attention?
Clear answers can support an informed discussion. They cannot eliminate uncertainty where adequate clinical evidence is missing.
Conclusion
Peptide treatment decisions require attention to the exact medication, clinical evidence, and current regulatory requirements. Availability alone cannot answer whether a treatment is appropriate for you.
Frequently Asked Questions
No. Compounded drugs are not FDA-approved, and FDA does not review each preparation for safety, effectiveness, and quality before marketing. A compounder must still meet applicable requirements.
No. The Pharmacy Compounding Advisory Committee gives nonbinding advice. A recommendation does not approve a drug or itself change the codified compounding list.
No. Evidence about a topical formulation does not establish the safety or effectiveness of injectable GHK-Cu. The formulation, intended use, and route of administration need their own evidence review.
Discuss Peptide Treatment Questions With Dr. Khan
If you have questions about peptides and the FDA, contact Internal Healing and Wellness MD to request a consultation with Dr. Khan about your health concerns and treatment options. A consultation does not guarantee that a particular peptide will be recommended or prescribed.
Disclosure: IHAWMD prescribes certain peptide medications and has a financial interest in those services. We use only reputable, state-licensed 503A compounding pharmacies and discuss the evidence and unknowns with you before any prescription.
Relevant Studies and References
- Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act, 21 C.F.R. § 216.23 (2026). https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.23
- Mateescu, D.-M., Gavrilescu, D.-M., Mincioaga, R.-I., Pah, A.-M., Toma, A.-O., Serban, D.-V., Avram, C. A., Craciun, M.-L., Enache, B., & Muresan, C.-O. (2026). GHK-Cu as a bioactive metallopeptide and drug-delivery cargo: Coordination chemistry, formulation science, therapeutic evidence, and a translational roadmap. Pharmaceutics, 18(9), Article 1077. https://doi.org/10.3390/pharmaceutics18091077
- Moiz, A., O’Keefe, E. L., & O’Keefe, J. H. (2026). Dangers of injectable peptides and other unregulated “biohacking” drugs. Missouri Medicine, 123(4), 337–343. https://pmc.ncbi.nlm.nih.gov/articles/PMC13585006/
- Poolton, J. T., Minett, J., & Kazmi, A. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: A systematic review of efficacy and safety. Acta Orthopaedica Belgica, 92(3). https://doi.org/10.52628/92.3.15837
- U.S. Department of Health and Human Services. (2026a, October 30). Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Federal Register, 91(209), 68526–68527. https://www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.htm
- U.S. Department of Health and Human Services. (2026b). HHS enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances [Draft policy]. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- U.S. Food and Drug Administration. (n.d.-a). Bulk drug substances used in compounding. Retrieved November 13, 2026, from https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding
- U.S. Food and Drug Administration. (n.d.-b). Bulk drug substances used in compounding under section 503A of the FD&C Act. Retrieved November 13, 2026, from https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food and Drug Administration. (n.d.-c). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Retrieved November 13, 2026, from https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- U.S. Food and Drug Administration. (n.d.-d). The drug development process. https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
- U.S. Food and Drug Administration. (n.d.-e). Understanding the risks of compounded drugs. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs
- U.S. Food and Drug Administration. (n.d.-f). Understanding unapproved use of approved drugs “off label”. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
- U.S. Food and Drug Administration. (2026a, May 11). BPC-157-related bulk drug substances (BPC-157 [free base] and BPC-157 acetate) [Briefing document for the Pharmacy Compounding Advisory Committee, July 23–24, 2026]. https://www.fda.gov/media/193343/download
- U.S. Food and Drug Administration. (2026b, May 14). Bulk drug substances nominated for use in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/94155/download
- U.S. Food and Drug Administration. (2026c, September 18). Empower Clinic Services, LLC dba Empower Pharmacy (Warning Letter No. 738238). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026
- U.S. Food and Drug Administration. (2026d, April 1). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- U.S. Food and Drug Administration. (2026e, July 23–24). July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- U.S. Food and Drug Administration. (2026f, May 1). List of bulk drug substances for which there is a clinical need under section 503B of the Federal Food, Drug, and Cosmetic Act. Federal Register, 91, 23431. https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- U.S. Food and Drug Administration. (2026g, August 24). Peak Performance Peptides (Warning Letter No. 735127). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-performance-peptides-735127-08242026
- U.S. Food and Drug Administration. (2026h, May 15). TB-500-related bulk drug substances (TB-500 [free base] and TB-500 acetate) [Briefing document for the Pharmacy Compounding Advisory Committee, July 23–24, 2026]. https://www.fda.gov/media/193349/download